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Systematic reviews (SR) may potentially contain reports of primary trials with ethical problems.
The Cochrane Collaboration SRs are considered as the highest standard in evidence‐based health
care resources. All SRs completed during the last 5 years (2013–2017) under the management of
the Oral Health Group of the Cochrane Collaboration were identified. All primary trials included
in the Oral Health Group SRs were identified and examined to establish their status regarding
pre‐hoc approval of an independent ethics committee (EC), often termed Institutional Review
Board (IRB) before commencing recruitment of trial participants. Ninety‐five SRs contained 960
primary trials, of which 272 (28.3%) were not examined by the author of this paper. Amongst
the remaining 688 primary trials, 198 (29%) contained no reference to study conduct approval
by a research ethics committee. The majority of primary studies referred to an EC/IRB approval
with or without identifying the name of the ethics committee (n = 401, 58%), whereas some
papers identified both the committee name and a protocol or reference number of the EC/IRB
approval (n = 89, 13%). The Cochrane Collaboration, along with other developers of SRs, should
adopt the policy established by COPE with regard to what to do if one suspect an ethical problem,
that is, request evidence of EC/IRB approval. All stakeholders should rest assured that clinical
policies and practices based on SRs are based on ethically sound clinical research.
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Some matters in evidence‐based medicine are taken for granted, such
as assuming that the primary trials in an otherwise methodologically
rigorous systematic review (SR) adhere to minimum research ethics
standards. Developers of systematic reviews should consider whether
or not a reported trial clarify that an independent human research
ethics committee had approved the research protocol before
commencing recruitment of trial participants. Regrettably, this
appears often not to be considered in most SRs, at least in the oral
and craniofacial research literature.
The Cochrane Collaboration SRs are internationally recognized as
the highest standard in evidence‐based healthcare resources. Yet, the
international Cochrane Collaboration provides little guidance on when- - - - - - - - - - - - - - - - - - - - - - - - - - -
e Creative Commons Attribution Li
ntal Research published by John Wto include or exclude an ethically dubious primary trial in a SR. Their
training website discusses publishing ethics issues, such as authorship
and contributorship, conflicts of interest, and libel and plagiarism
(Cochrane Collaboration Training Website, 2017) but nothing about
ethical aspects of the primary trials. Moreover, the pertinent section
in their handbook on protection of human subjects and animals in
research has been marked for several years with “We are working on
this section” (Cochrane Collaboration Handbook, 2016a). The lack of
focus raises the question whether Cochrane SRs may potentially
contain reports of primary trials with ethical problems.
It is unknown how many of the existing Cochrane SRs that include
trials without a statement about a pre‐hoc research ethics approval. It
is also unknown whether the proportion of such trials varies amongst
the different medical disciplines and sub‐disciplines. The objective of- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
cense, which permits use, distribution and reproduction in any medium, provided
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recent Cochrane SRs within the domains of dental and oral health that
contain no explicit statement of a pre‐hoc ethics approval.2 | MATERIALS AND METHODS
The author identified all SRs completed during the last five years
(2013–2017) under the management of the Oral Health Group
(OHG) of the Cochrane Collaboration (OHG of the Cochrane Collabo-
ration, 2017). The list of SRs was verified against the references
identified in Medline by way of Pubmed using the search term
“Cochrane Database Syst Rev”[jour] AND (dentistry OR dental OR
“oral health”). The references were exported to EndNote X8.0.1 (Bld 1;
Clarivate Analytics, New York, USA) and thereafter to a relational database
(Microsoft Access 2016 [ver. 16.0.4229.1024]), run under Windows 10
operating system (Microsoft, Redmond, Washington, U.S.A.)
All primary trials that were included in the OHG SRs were identi-
fied, and these references were merged into the relational database.
All primary trials that were accessible digitally were read in full to
establish their status regarding pre‐hoc research ethics approval
before commencing recruitment of trial participants. The terms
“Institutional Research Board” (IRB) and “(Human) (Research) Ethics
Committee” (EC) and any permutations thereof were considered as
synonyms. Three categories of textual references to EC/IRB were
identified; that is, either an EC/IRB was named with approval number
and/or date or some reference was made to an EC/IRB, alternatively,
there was no reference to any EC/IRB. Any referring to the Declaration
of Helsinki was not considered equivalent to a formal EC/IRB approval.
The extracted tabular data were not subjected to further statistical
analyses.3 | RESULTS
Since January 2013, 98 SRs have been published or updated, of which
the great majority focus on effects of an intervention (n = 95). Three
SRs dealing with epidemiology of water fluoridation (Iheozor‐Ejiofor
et al., 2015) and precision of diagnostics tests for cancer (MaceyTABLE 1 Description of approval by an ethics committee in the primary t
reviews published since January 2013 (n = 95)
Period 1970 ← 1970–1979 1980–1984 1985–1989 199
Approved, with
identifier
0 0 0 0
Approved 0 0 0 1
Not mentioned 4 6 7 13 1
Paper not
examined
6 33 18 24 4
Sum 10 39 25 38 6
Proportions % % % % %
Approved, with
identifier
0.0 0.0 0.0 0.0 0.
Approved 0.0 0.0 0.0 2.6 9.
Not mentioned 40.0 15.4 28.0 34.2 20.
Paper not
examined
60.0 84.6 72.0 63.2 70.et al., 2015), (Walsh et al., 2013) were not considered further. The 95
SRs that were focused on effects of an intervention contained either
no primary trials (n = 16 SRs) or presented extracted data from one
(n = 13 SRs) up to 56 primary trials. Altogether, the 95 SRs contained
960 primary trials published between 1964 and 2016, of which 272
(28.3%) were not examined by the author of this paper. The reasons
were predominantly due to no reading access (n = 115), paper was
not available online (n = 88), non‐English language (n = 38), or for other
reasons (abstract only, letter to the editor, and dissertation).
Amongst the 688 primary trials available digitally in English for full
text reading, 198 (29%) contained no reference to any EC/IRB,
whereas the majority referred to an EC/IRB (n = 401, 58%) and even
included the protocol number of the EC/IRB approval (n = 89, 13%).
A marked change of the proportions of primary trials with and
without a reference to an EC/IRB is apparent over time (Table 1).
The first paper that describes an ethics approval in the identified pool
of primary trials was published as late as 1989(Baab & Johnson, 1989).
Since 2010, the vast majority of the primary trials describe that they
were pre‐hoc approved by an EC/IRB.4 | DISCUSSION
The question whether it is necessary that an EC/IRB needs to approve
a human clinical trial before commencing recruitment of trial partici-
pants should today be a non‐issue. A requirement for a pre‐hoc
approval by an IRB was introduced in 1974 in USA (National Research
Act, 1974) and rapidly included as Article 2 in the first revision of the
Declaration of Helsinki in October 1975(World Medical Association,
1975). Succeeding requirements were formulated in the Belmont
report written by the National Commission for the Protection of
Human Services of Biomedical and Behavioral Research in USA in
1977, and by the joint Council for International Organizations of
Medical Sciences and the World Health Organization in 1982. The
United Nations Educational, Scientific and Cultural Organization have
even included the requirement under Article 19 in the 2005 Universal
Declaration on Bioethics and Human Rights (United Nations
Educational, Scientific and Cultural Organization, 2017). The publishingrials (n = 960) identified in all Cochrane Oral Health Group systematic
0–1994 1995–1999 2000–2004 2005–2009 2010→ All
0 0 6 26 57 89
6 34 54 148 158 401
3 29 44 44 38 198
6 33 28 48 36 272
5 96 132 266 289 960
% % % % %
0 0.0 4.5 9.8 19.7 9.3
2 35.4 40.9 55.6 54.7 41.8
0 30.2 33.3 16.5 13.1 20.6
8 34.4 21.2 18.0 12.5 28.3
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minimum requirements for manuscript contents, as detailed by, for
example, the World Association of Medical Editors, the International
Committee of Medical Journal Editors and the Committee on
Publication Ethics (COPE). The references above are an incomplete list
of source documents. Claims have been made that it borders to
research misconduct today to initiate a human trial without proper
pre‐hoc EC/IRB approval before commencing recruitment of trial
participants. There has been some considerations about how authors
of Cochrane SRs may expose research misconduct, but issues about
pre‐hoc EC/IRB approval has not been specifically mentioned (Vlassov
& Groves, 2017).
Several of the current Cochrane SRs on oral and craniofacial med-
icine contain a disproportional fraction of primary trials with no state-
ment about EC/IRB approval. Not only individual clinicians but also
national and commercial health bodies develop clinical policies and
practices that rely heavily on Cochrane SRs. Moreover, the Cochrane
Collaboration is doing an excellent job promoting sensible guidance
for lay people about the therapy effectiveness of different ailments
and conditions (Cochrane Collaboration, 2016). In the opinion of the
author, all readers need to be informed on whether the primary trials
have been approved by an ethics committee. It is an ethical dilemma
for all stakeholders to decide whether health recommendations should
and can be founded on primary trials with possible questionable
research ethics.
The Cochrane Collaboration has established clear guidelines for
ethical considerations in their Editorial and Publishing Policy Resources
and are extremely cognizant of potential risk of bias in trials. A recent
survey amongst experts and stakeholders on how to improve the
Cochrane Collaboration's tool for assessing the risk of bias is perhaps
representative (Savović et al., 2014). Apart from the positive element
that the survey had been pre‐hoc approved by the Ottawa Hospital
Research Institute Ethics Committee, the investigators apparently did
not solicit anyone's opinions about possible association between lack
of EC/IRB approval and risk of potential bias. Perhaps this is just a
reflection of the mentality of ethically cognizant researchers that some
matters in clinical research are plainly obvious. This perception is rein-
forced by a quote from the Cochrane handbook in the section on risk
of bias in nonrandomized studies: “Because of the need for research
ethics approval, all randomized trials must have a protocol” (Cochrane
Collaboration Handbook, 2016b).
The intention of this paper was not to single out particular factors
associated with characteristics of the primary trials with regard to, for
example, topic, the type of journal or the origin of the investigators.
Rather, it was to focus on the need to base our clinical policies and
practices on ethically sound primary trials. For the interested reader,
further details about the EC/IRB status of the 960 primary trials may
be sourced from the Supporting Information located on the website
of Clinical and Experimental Dental Research (Clinical and Experimen-
tal Dental Research, 2017).
It is unknown whether the limited proportion of primary trials in
compliance with proper publishing ethics is representative for
Cochrane SRs within other medical domains. It seems sensible to
conduct comparable analyses amongst other biomedical fields in the
existing pool of Cochrane SRs.The 11,578+ editors of journals that currently are members of
COPE are expected to follow the COPE Code of Conduct for Journal
Editors (The COPE Code of Conduct for Journal Editors, 2017), which
includes assuring that research involving humans and animals is ethical.
The practical guidance is that “editors should seek assurances that all
research has been approved by an appropriate body where one exists”.
It follows that journal editors have a primary duty to ensure that ethical
approval is reported.
The lack of documented EC/IRB approval in a primary trial does
not necessarily invalidate its conclusions, or by extension, conclusions
in an SR based on aggregated data from such trials. The reason is that
one cannot discount completely that the clinical investigators did
indeed have an EC/IRB approval but forgot to add this information in
the manuscript and both the journal referees and the editor simply
had a bad day.
One solution to rectify the current predicament is that the
Cochrane collaboration, along with other developers of SRs, adopts
the policy established by COPE with regard to what to do if one
suspects an ethical problem (Committee on Publication Ethics (COPE),
2017), that is, request documented evidence of EC/IRB approval.
Moreover, one cannot rule out that conclusions in current SRs may
potentially change if the primary trials without EC/IRB approval are
disregarded. With regard to Cochrane SRs, the collaboration needs to
decide on whether the editorial team of the Cochrane special groups
should be responsible for verifying EC/IRB approvals in case of doubts,
or if this should be left to the SR authors. The question may perhaps
require some legal consultations due to potential unanticipated ramifi-
cations. Regardless, the essential issue is that all stakeholders may rest
assured that clinical policies and practices based on Cochrane SRs are
based on ethically sound clinical research.
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